Topical retapamulin in the management of infected traumatic skin lesions

Area of Science:

• Microbiology
• Pharmacology
• Dermatology

Background:

• Retapamulin is a novel semisynthetic pleuromutilin antibiotic developed for topical application.
• Its unique mechanism of action inhibits bacterial protein synthesis, distinct from other ribosome-targeting agents.
• This minimizes potential cross-resistance with existing antibacterial classes.

Purpose of the Study:

• To evaluate the efficacy and safety of retapamulin as a topical agent for skin and skin-structure infections (SSSIs).
• To assess its activity against common Gram-positive pathogens, including antibiotic-resistant strains.
• To compare retapamulin's effectiveness with standard oral treatments for specific SSSIs.

Main Methods:

• In vitro studies assessed retapamulin's potency against various bacterial pathogens.
• Clinical trials compared topical retapamulin (twice-daily for 5 days) with oral cephalexin (10 days) for secondarily infected traumatic lesions.
• Approved clinical use involves a 1% retapamulin ointment for impetigo.

Main Results:

• Retapamulin demonstrated high in vitro potency against Staphylococcus aureus, Streptococcus pyogenes, and coagulase-negative staphylococci.
• It showed efficacy against S. aureus strains resistant to macrolides, fusidic acid, or mupirocin.
• Clinical studies found topical retapamulin comparable to oral cephalexin for treating infected traumatic lesions.

Conclusions:

• Retapamulin offers a novel mechanism of action with low cross-resistance potential.
• It is highly effective against key pathogens causing SSSIs.
• Retapamulin represents a valuable topical treatment option for impetigo and other skin infections.